Ovarian Cancer: Implications for the Pharmacist
|
|
- Isabel Newman
- 5 years ago
- Views:
Transcription
1 Ovarian Cancer: Implications for the Pharmacist Megan May, Pharm.D., BCOP Objectives Describe the etiology and pathophysiology of ovarian cancer Outline the efficacy and safety of treatment options for ovarian cancer Explain the mechanism of action of poly ADP ribose polymerase inhibitors (PARP inhibitors) available for ovarian cancer Explain how to evaluate the appropriate selection of therapy for specific ovarian cancer patients 1
2 Epidemiology 5 th most frequent cause of death in women Incidence in 2018 New cases: 22,240 Deaths: 14,070 Primarily post-menopausal disease Median age at diagnosis: years old Caucasians > African American National Cancer Institute Etiology/Pathogenesis Sporadic ovarian cancer etiology unknown Most common type (85-90%) Familial and hereditary syndromes Less common type (10-15%) Incessant ovulation theory Risk of developing ovarian cancer is related to number of ovulatory cycles Tumor suppressor genes BRCA1, BRCA2, p53 National Cancer Institute
3 Pathology Epithelial adenocarcinoma Serous Mucinous Endometroid Clear-cell Germ-cell tumor Sex-cord stromal Metastatic from other malignancies Risk Factors Early menarche, late menopause and nulliparity Increased age Prolonged use of ovulatory stimulating drugs Environmental and dietary factors Residence in North American or Northern Europe Caucasian race Genetic factors Hormone replacement therapy 3
4 Hereditary Risk Family History of Ovarian Cancer Lifetime Risk None % 1 first degree relative 3 5% 2 first-degree relatives 7 9% Lynch Syndrome 6 10% Known BRCA 1 and/or BRCA % germline mutation Ovarian Cancer Research Fund Alliance: Risk Factors. Favorable Factors Multiple pregnancies Breastfeeding Use of prolonged oral contraceptives Tubal ligation Prophylactic oophorectomy 4
5 Screening No effective screening test for ovarian cancer Low/standard risk (not familial or hereditary) Annual physical and pelvic examination High risk (hereditary ovarian cancer, BRCA 1 or BRCA 2 positive) Pelvic examination, transvaginal ultrasound and CA 125 every 6 12 months starting at age Gynecol Oncol 2007; 104:S14. Abstract 10 Prevention Oral contraceptives Use for five or more years decreases risk of ovarian cancer by 50% or more Longer the use, greater the protection Protection can continue for up to 30 years after stopping use Prophylactic oophorectomy Decreases risk of ovarian cancer in high risk patients 5
6 Signs and Symptoms Bloating Pelvic or abdominal pain Eating satiety Urinary symptoms (frequency or urgency) GI symptoms Pulmonary symptoms Unilateral or bilateral, solid, cystic and/or complex pelvic or adnexal masses CA-125 highly elevated Staging International Federation of Gynecologic Oncologists (FIGO) and AJCC staging systems stems (stages I-IV) IV) Grade 1: well differentiated 2: moderately differentiated 3: poorly differentiated AJCC Cancer Staging Manual, Sixth Edition (2002) 6
7 FIGO Staging Stage I Growth limited to the ovaries Stage II Growth involving one or both ovaries with pelvic extension Stage III Tumor involving one or more ovaries with tumor outside the pelvis and/or positive retroperitoneal or inguinal lymph nodes Superficial liver metastases Tumor limited to pelvis but malignant extension to small bowel or omentum Stage IV Growth involving one or more ovaries with distant metastases Parenchymal liver metastases Pleural effusion must have positive cytology AJCC Cancer Staging Manual, Sixth Edition (2002) Prognosis Stage of disease Volume of residual disease at time of surgery Histologic subtype and grade CA-125 Stage of Disease % of Cases 5-year Survival I 23 90% II 13 70% III % IV 16 17% Principles and Practice of Gyn Oncol: 3 rd Ed. 7
8 Primary Treatment (Stages I-II) Comprehensive surgical staging Optimal: < 1 cm residual disease Suboptimal: > 1 cm residual disease Adjuvant combination chemotherapy Taxane + platinum Number of cycles (3 or 6) varies by stage Observation in stage 1A or 1B PDQ Adult Treatment Editorial Board. PDQ Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment. Bethesda, MD: National Cancer Institute. Updated 07/19/2018. Available at: Accessed 09/04/2018. GOG-157 Early stage ovarian cancer, high-risk features (n = 457) Randomized following surgery to 3 vs. 6 cycles of paclitaxel + carboplatin Recurrence rate 33% lower in patients treated with 6 cycles (HR: 0.627, not statistically significant) Grade 2 neurotoxicity in 2% vs. 11% patients Bell J, et al. Gynceol Oncol. 2006;102(3):
9 ICON-1 Trial Early stage, high-grade, or surgically unstaged tumors (n = 477) Randomized, prospective, multi-center Randomized following surgery to 6 cycles of platinum-based chemotherapy vs. observation 5-year survival Progression-free survival (PFS) Platinum x 6 79% 73% Observation 70% 62% Trimbos JB, et al. J Natl Cancer Inst. 2003;95(2): ACTION Trial Randomized, prospective, multi center trial, early stage high grade tumors only (n = 448) Stage IA or IB well differentiated tumors excluded Following surgery, patients randomized to receive 4 cycles of platinum based chemotherapy vs. observation Included grade 2 3 tumors only At median follow up 5.5 years, no statistical difference in overall survival (OS) or PFS Statistically significant survival benefit only seen in sub group analysis of patients who did not undergo optimal surgical staging Trimbos JB, et al. J Natl Cancer Inst. 2003;95(2):
10 Advance Stage (Stages III-IV) Comprehensive surgical staging Six cycles of adjuvant combination chemotherapy with taxane + platinum or liposomal doxorubicin + carboplatin Intraperitoneal chemotherapy may be an option in stage II or III Occasionally, neoadjuvant chemotherapy PDQ Adult Treatment Editorial Board. PDQ Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment. Bethesda, MD: National Cancer Institute. Updated 07/19/2018. Available at: Accessed 09/04/2018. Adjuvant Chemotherapy GOG-111 Paclitaxel + cisplatin improves median survival compared to cyclophosphamide + cisplatin GOG-158 Paclitaxel + carboplatin preferred over paclitaxel + cisplatin due to equal efficacy and reduced toxicity SCOTROC trial Docetaxel is equally efficacious and less neurotoxic than paclitaxel when given in combination with carboplatin Muggia F, et al. JCO. 2000;18(1): Bookman MA, et al. Int J Gynecol Cancer. 2003;13(6): Vasey PA, et al. J Natl Cancer Inst. 2004;96:
11 Cisplatin versus Carboplatin Neurotoxicity Nephrotoxicity N/V Cisplatin +++ *paclitaxel 24h infusion Carboplatin + *paclitaxel 3h infusion In patients with optimally resected stage III ovarian cancer Complete remission and overall survival not different between cisplatin/paclitaxel and carboplatin/paclitaxel Carboplatin regimen easier to administer Ozols RF JCO 2003;21: ; GOG 158 Paclitaxel versus Docetaxel Neurotoxicity Greater grade 2 & 3 neuropathy with paclitaxel l Neutropenia Greater grade 4 neutropenia with docetaxel Edema Greater with docetaxel 11
12 IP Therapy Patient selection Stage IIIC (optimal surgical cytoreduction) Good performance status No history of prior bowel surgery or bowel surgery at the time of primary therapy Benefits Substantial improvement in overall survival Risks Infection Leukopenia Dehydration, electrolyte abnormalities Catheter malfunction Abdominal pain Armstrong DK, et al. N Engl J Med. 2006;354: GOG-172 Stage IIIC ovarian and primary peritoneal cancer and optimal surgical cytoreduction ction were randomized to one of the following (n = 429): IV regimen Paclitaxel 135 mg/m 2 IV over 24 hours on Day 1 + cisplatin 75 mg/m 2 IV on Day 2 every 3 weeks IP regimen Paclitaxel 135 mg/m 2 IV over 24 hours on Day 1 + cisplatin 100 mg/m 2 IP on day 2 + paclitaxel 60 mg/m 2 IP on day 8 every 3 weeks Armstrong DK, et al. N Engl J Med. 2006;354:
13 GOG-172 Median PFS and OS at five years significantly improved for patients on IP treatment arm (18.3 vs months and 49.7 vs 65.6 months, respectively) Grade 3 and 4 toxicities were significantly worse in patients treated with IP therapy Only 42% of patients randomized to IP therapy completed six cycles of treatment (median=3) Patients unable to tolerate IP therapy were switched to the IV treatment arm QOL was significantly worse for patients in the IP arm while on treatment At 12 months, there was no difference in QOL between the two groups Armstrong DK, et al. N Engl J Med. 2006;354: Bevacizumab FDA-approved in combination with liposomal doxorubicin, paclitaxel, or topotecan OCEANS Trial AURELIA Trial Bevacizumab in combination with paclitaxel + carboplatin GOG-0213 Bevacizumab monotherapy GOG-0170D CCC-PHII-45 PDQ Adult Treatment Editorial Board. PDQ Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment. Bethesda, MD: National Cancer Institute. Updated 07/19/2018. Available at: Accessed 09/04/
14 GOG-218 Phase III randomized, double blind trial Patients with stage III or IV, any gross residual disease (n = 1873) Following surgery, patients were randomized standard chemotherapy (paclitaxel + carboplatin) cycles 1 6 and either Placebo (cycle 2 5) followed by placebo every 3 weeks for 15 months Bevacizumab 15 mg/kg (cycle 2 5) followed by placebo every 3 weeks for 15 months Bevacizumab 15 mg/kg (cycle 2 5) followed by bevacizumab 15 mg/kg every 3 weeks for 15 months Burger RA, et al. J Clin Oncol. 2010;28:18S GOG-218 Statistically significant increase in PFS for patients treated on the chemotherapy + bevacizumab + bevacizumab maintenance (14.1 months) vs. chemotherapy + bevacizumab + placebo maintenance (11.2 months) vs. chemotherapy alone (10.3 months) (HR=0.72) Preliminary OS data shows no difference between groups No difference in QOL detected between any of the three groups Burger RA, et al. J Clin Oncol. 2010;28:18S 14
15 ICON-7 Phase III, randomized, open label Patients with stage I IV, optimal or suboptimal disease (n=1528) Following surgery, patients were randomized Standard chemotherapy Chemotherapy + bevacizumab 7.5 mg/kg every 3 weeks followed by bevacizumab 7.5 mg/kg maintenance every 3 weeks for 12 cycle (total one year of bevacizumab) Perren TJ, et al. N Engl J Med. 2011;365: ICON-7 At 42 months, the median PFS was modestly improved in the treatment arm vs. the control arm (24.1 months vs months, HR=0.81) Effect of bevacizumab was greater in patients at high risk for progression (PFS 18 months vs months) Median OS was improved in the high risk patient population (36 months vs. 28 months) Toxicity was greater in the bevacizumab treated patients Perren TJ, et al. N Engl J Med. 2011;365:
16 Recurrent, Refractory, and Resistant Ovarian Cancer 60 80% of ovarian cancer patients Length of subsequent remissions is shorter than the initial remission Goal of treatment Improve/eliminate symptoms Achieve an objective response Improve quality of life Delay time to symptomatic disease Prolong survival if possible PDQ Adult Treatment Editorial Board. PDQ Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment. Bethesda, MD: National Cancer Institute. Updated 07/19/2018. Available at: Accessed 09/04/2018. Definitions Platinum sensitive disease Initial response to platinum Duration of initial remission > 6 months Longer the initial remission, the greater the likelihood of responding to second and third line agents Probability of response to chemotherapy is 30% or more Platinum resistant disease Initial response to platinum Duration of initial remission < 6 months Probability bilit of response to additional treatment t t is 10 15% 15% Primary progressive (platinum refractory) disease No response and/or progression of disease during primary therapy with platinum Worst prognosis Probability of response to additional chemotherapy <10% PDQ Adult Treatment Editorial Board. PDQ Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment. Bethesda, MD: National Cancer Institute. Updated 07/19/2018. Available at: Accessed 09/04/
17 Recurrent Ovarian Cancer Platinum-containing chemotherapy regimens Bevacizumab Chemotherapy and/or bevacizumab PARP inhibitors Clinical trial Cytoreductive surgery PDQ Adult Treatment Editorial Board. PDQ Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment. Bethesda, MD: National Cancer Institute. Updated 07/19/2018. Available at: Accessed 09/04/2018. Recurrent Ovarian Cancer Platinum Sensitive Cisplatin/Carboplatin + paclitaxel Carboplatin + liposomal doxorubicin Carboplatin + gemcitabine +/- bevacizumab Cisplatin + gemcitabine Carboplatin + albumin-bound paclitaxel Carboplatin + docetaxel Carboplatin Cisplatin Can consider abdominal radiotherapy Resistant Docetaxel Liposomal doxorubicin Gemcitabine + docetaxel Etoposide (oral) Topotecan Dose-dense paclitaxel Addition of bevacizumab PDQ Adult Treatment Editorial Board. PDQ Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment. Bethesda, MD: National Cancer Institute. Updated 07/19/2018. Available at: Accessed 09/04/
18 PARP Inhibitors Poly ADP-ribose polymerase inhibitor DNA repair mechanism BRCA mutated cells more dependent on this mechanism Directly inhibits PARP 1, 2, 3 and increases formation of PARP-DNA complexes, preventing DNA repair cell death FDA- approved PARP inhibitors Rucaparib (Rubraca ) Olaparib (Lynparza ) Niraparib (Zejula ) PDQ Adult Treatment Editorial Board. PDQ Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment. Bethesda, MD: National Cancer Institute. Updated 07/19/2018. Available at: Accessed 09/04/2018. FDA-Approved Ovarian Cancer Indications Rucaparib Treatment of advanced ovarian cancer with gbrca or sbrca 2 prior lines of chemotherapy Maintenance treatment of recurrent ovarian cancer in complete or partial response to platinum-based chemotherapy Olaparib Treatment of advanced ovarian cancer with gbrca 3 prior lines of chemotherapy Maintenance treatment of recurrent ovarian cancer in complete or partial response to platinum-based chemotherapy Niraparib Maintenance treatment of recurrent ovarian cancer in complete or partial response to platinum-based chemotherapy Rubraca [prescribing information]. Clovis Oncology Lynparza [prescribing information]. AstraZenca Zejula [prescribing information]. Tesaro
19 FDA-Approved Dosing Rucaparib 600 mg by mouth twice daily Tablet available: 200 mg, 250 mg, 300 mg Olaparib 400 mg capsule by mouth twice daily Capsule available: 50 mg 300 mg tablet by mouth twice daily Tablet available: 100 mg and 150 mg Niraparib 300 mg by mouth once daily Capsule available: 100 mg Rubraca [prescribing information]. Clovis Oncology Lynparza [prescribing information]. AstraZenca Zejula [prescribing information]. Tesaro Treatment versus Maintenance Therapy Treatment An initial iiil treatment used in attempt to shrink hik the current tumor Maintenance therapy Continuing to treat after completion of standard round of chemotherapy Used to avoid or slow the cancer s return Slow the growth of advanced cancer after the initial treatment 19
20 Risk/Benefits of Maintenance Therapy Benefits May help keep cancer from coming back May slow down cancer growth Disadvantages Side effects Treatment cost More doctor visits Limited information on long term side effects and benefits for each individual PARP Inhibitor Side Effects All have a similar side effects, but some are more common and/or more severe ere in one versus s another Acute myeloid leukemia/myelodysplastic syndrome has been reported in 0.5%-2% of patients Thompson LA. Oncology Nurse Advisor
21 ARIEL2: Rucaparib Outcome BRCA Mutation n = 40 BRCA Wild-Type and LOH High n = 82 BRCA Wild-Type and LOH Low n = 70 ORR, % PFS, months p value (vs LOH-low) 12.8 < Duration of response, months p value (vs LOH-low) LOH = loss of heterozygosity ORR = objective response rate Swisher EM, et al. Lancet Oncol 2017;18: ARIEL3: Rucaparib Outcome BRCA Mutation Overall Study Population Rucaparib Placebo Rucaparib Placebo n = 130 n = 66 n = 375 n = 189 Median PFS, months Coleman RL, et al. Lancet 2017;390(10106):
22 Rucaparib Adverse Effects in 20% of Patients Adverse Effects All Grades (%) n = 377 Grades 3/4 (%) n = 377 Nausea 77 5 Vomiting 46 4 Constipation 40 2 Diarrhea 34 2 Abdominal Pain 32 3 Asthenia/Fatigue Anemia Thrombocytopenia 21 5 Dysgeusia Decreased appetite 39 3 Dyspnea Swisher EM, et al. Lancet Oncol 2017;18: Rubraca [prescribing information]. Clovis Oncology Rucaparib Laboratory Abnormalities in 35% of Patients Laboratory Parameter All Grades (%) n = 377 Grades 3/4 (%) n = 377 Increase in creatinine 92 1 Increase in ALT Increase in AST 73 5 Increase in cholesterol 40 2 Decrease in hemoglobin Decrease in lymphocytes 45 7 Decrease in platelets 39 6 Decrease in absolute neutrophil count Swisher EM, et al. Lancet Oncol 2017;18: Rubraca [prescribing information]. Clovis Oncology
23 SOLO-2: Olaparib Outcome Olaparib n = 196 Placebo n = 99 PFS, months Grade 3 or 4 adverse effects 18% 8% Pujade-Lauraine E, et al. Lancet Oncol. 2017;18(9): Olaparib Adverse Effects in 20% of Patients Adverse Effects All Grades (%) Grades 3/4 (%) Olaparib n = 195 Placebo n = 99 Olaparib n = 195 Placebo n = 99 Anemia Nausea Vomiting Diarrhea Stomatitis Nasopharyngitis/upper respiratory infection/sinusitis/rhinitis/influenza Fatigue Decrease appetite Arthralgia/myalgia Dysgeusia Headache Pujade-Lauraine E, et al. Lancet Oncol. 2017;18(9): Lynparza [prescribing information]. AstraZenca
24 Olaparib Laboratory Abnormalities in 25% of Patients Laboratory Parameter All Grades (%) Grades 3/4 (%) Olaparib Placebo Olaparib Placebo n = 195 n = 99 n = 195 n = 99 Increase in mean corpuscular volume Decrease in hemoglobin Decrease in leukocytes Decrease in lymphocytes Decrease in absolute neutrophil count Increase in serum creatinine Increase in platelets Pujade-Lauraine E, et al. Lancet Oncol. 2017;18(9): Lynparza [prescribing information]. AstraZenca NOVA: Niraparib Outcome BRCA Mutation BRCA Wild-Type Niraparib Placebo Niraparib Placebo n = 138 n = 65 n = 234 n = 116 Median PFS, months Mirza MR, et al. N Engl J Med. 2016;375:
25 Niraparib Adverse Effects in 20% of Patients Adverse Effects All Grades (%) Grades 3/4 (%) Niraparib n = 367 Placebo n = 179 Niraparib n = 367 Placebo n = 179 Thrombocytopenia Anemia Neutropenia Nausea Constipation Vomiting Abdominal pain/distention Mucositis/stomatitis Diarrhea Fatigue/asthenia Mirza MR, et al. N Engl J Med. 2016;375: Zejula [prescribing information]. Tesaro Niraparib Adverse Effects in 20% of Patients Adverse Effects All Grades (%) Grades 3/4 (%) Niraparib Placebo Niraparib Placebo n = 367 n = 179 n = 367 n = 179 Decreased appetite Headache Nasopharyngitis Dyspnea Rash Hypertension Mirza MR, et al. N Engl J Med. 2016;375: Zejula [prescribing information]. Tesaro
26 Niraparib Laboratory Abnormalities in 25% of Patients Laboratory Parameter All Grades (%) Grades 3/4 (%) Niraparib Placebo Niraparib Placebo n = 367 n = 179 n = 367 n = 179 Decrease in hemoglobin Decrease in platelet count Decrease in WBC count Decrease in absolute neutrophil count Increase in AST Increase in ALT Mirza MR, et al. N Engl J Med. 2016;375: Zejula [prescribing information]. Tesaro Summary Clinical staging is important in determining the appropriate treatment New advances for patients with ovarian cancer with the PARP inhibitors Olaparib and rucaparib is approved in treatment and maintenance Niraparibib is approved in maintenance Treatment should always be individualized 26
27 Ovarian Cancer: Implications for the Pharmacist Megan May, Pharm.D., BCOP 27
Drug Niraparib Olaparib
Dear NCCN Value Pathway Committee, We are making this submission to provide information that we believe is relevant for developing NCCN Categories of Preference for the use of PARP inhibitors in recurrent
More informationTable Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies
Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Uterus Study N Eligibility Regimen RR (No. of Responses) Median OS Grade 3/4 Toxicities Nimeiri et al[42] Total:
More informationWinship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer
Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Ira R. Horowitz, MD, SM, FACOG, FACS John D. Thompson Professor and Chairman Department of Gynecology
More informationSOLO-1. Dott.ssa Elisabetta Sanna U.O.C. Ginecologia Oncologica- AOB Cagliari Direttore: Dott. Antonio Macciò
SOLO-1 maintenance therapy in patients with newly diagnosed advanced ovarian cancer following platinum-based chemotherapy Dott.ssa Elisabetta Sanna U.O.C. Ginecologia Oncologica- AOB Cagliari Direttore:
More informationCurrent state of upfront treatment for newly diagnosed advanced ovarian cancer
Current state of upfront treatment for newly diagnosed advanced ovarian cancer Ursula Matulonis, M.D. Associate Professor of Medicine, HMS Program Leader, Medical Gyn Oncology Dana-Farber Cancer Institute
More informationACRIN Gynecologic Committee
ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic
More informationLynparza. Lynparza (olaparib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 5 Last Review Date: March 16, 2018 Lynparza Description Lynparza (olaparib)
More informationUpdate on PARP inhibitors
Professor of Medicine Harvard Medical School Boston MA Update on PARP inhibitors Ursula Matulonis, M.D. Chief, Division of Gynecologic Oncology Brock-Wilson Family Chair Dana-Farber Cancer Institute History
More informationNCCN Guidelines for Ovarian Cancer V Meeting on 11/15/17
OV-1 External request: Submission from Vermillion/ASPiRA Laboratories to consider: Inclusion of the following recommendation in the workup for suspected ovarian cancer: OVA1 and/or Multivariate Index Assay
More informationHitting the High Points Gynecologic Oncology Review
Hitting the High Points is designed to cover exam-based material, from preinvasive neoplasms of the female genital tract to the presentation, diagnosis and treatment, including surgery, chemotherapy, and
More informationRubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer
Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer Rubraca is now indicated as maintenance treatment for women with recurrent ovarian cancer who are in a complete
More informationSafety Findings From FORWARD II: A Phase Ib Study Evaluating the Folate Receptor Alpha (FR
Safety Findings From FORWARD II: A Phase Ib Study Evaluating the Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC) Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab,
More information2/21/2016. Cancer Precision Medicine: A Primer. Ovarian Cancer Statistics and Standard of Care in 2015 OUTLINE. Background
Cancer Precision Medicine: A Primer Rebecca C. Arend, MD Division of Gyn Oncology OUTLINE Background Where we are Where we have been Where we are going Targeted Therapy in Ovarian Cancer How to Individualized
More informationLynparza. Lynparza (olaparib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 4 Last Review Date: September 15, 2017 Lynparza Description Lynparza
More informationCurrent Medical Oncology Approaches to Gynecologic Cancers. Mihaela Cristea, MD Associate Professor Medical Oncology
Current Medical Oncology Approaches to Gynecologic Cancers Mihaela Cristea, MD Associate Professor Medical Oncology Nothing to disclose DISCLOSURE Ovarian Cancer Objectives: a. To discuss new FDA approved
More informationControversies in the Management of Advanced Ovarian Cancer
안녕하세요 Controversies in the Management of Advanced Ovarian Cancer Mansoor R. Mirza Nordic Society of Gynaecological Oncology (NSGO) & Rigshospitalet Copenhagen University Hospital, Denmark Primary Debulking
More informationA New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG
A New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG Arizona Oncology (US Oncology Network) Professor, Gynecologic Oncology University of Arizona and Creighton
More informationFoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
More informationVirtual Journal Club. Ovarian Cancer. Reference Slides. Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies
Virtual Journal Club Ovarian Cancer Reference Slides Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies Mansoor R. Mirza, MD Copenhagen University Hospital Rigshospitalet
More informationClinical Trials. Ovarian Cancer
1.0 0.8 0.6 0.4 0.2 0.0 < 65 years old 65 years old Events Censored Total 128 56 184 73 35 108 0 12 24 36 48 60 72 84 27-10-2012 Ovarian Cancer Stuart M. Lichtman, MD Attending Physician 65+ Clinical Geriatric
More informationGOG-172: Survival Outcomes
CHEMOTHERAPY GOG-172: Survival Outcomes Progression-Free Survival Overall Survival Proportion Progression-Free 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 Rx Group IV IP PF Failed Total 50 160 210 63 142
More informationThe Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology
The Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology April 26, 2013 Larry J. Copeland M.D. Thank You for Your Friendship! 1982 1996 2013 The Ohio State University
More informationDr Sarah Mc Kenna, Consultant Medical Oncologist and Dr Joanne Millar, Consultant Medical Oncologist
Title: Systemic Anti-Cancer Therapy (SACT) Guidelines for Ovarian Cancer Author(s) Ownership: Approval by: Operational Date: Dr Sarah Mc Kenna, Consultant Medical Oncologist and Dr Joanne Millar, Consultant
More informationMedical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia
Tunisian Health System: Social Welfare with a Public insurance for all citizens including Indigent persons. (± Additional private insurance) Choice: Public Hospital/Private Clinics (Indigents Public H)
More informationTrial record 1 of 1 for:
Find Studies About Studies Submit Studies Resources About Site Trial record 1 of 1 for: YO39523 Previous Study Return to List Next Study A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel,
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 1Q17 January February
BRAND NAME Rubraca GENERIC NAME rucaparib MANUFACTURER Clovis Oncology, Inc. DATE OF APPROVAL December 19, 2016 PRODUCT LAUNCH DATE December 19, 2016 REVIEW TYPE Review type 1 (RT1): New Drug Review Full
More informationInhibidores de PARP en cáncer de ovario
Inhibidores de PARP en cáncer de ovario Ma Pilar Barretina Ginesta Servicio Oncología Médica Hospital Universitari Dr. J. Trueta Institut Català d Oncologia Coordinación científica: Dr. Fernando Rivera
More informationOVARIAN CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
1 OVARIAN CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Source: UpToDate 2017, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze (Gynecologic
More informationAHFS Final. IV and intraperitoneal regimen for. Criteria Used in. Strength. Strength. Use: Based on. taxane (either IV. following
AHFS Final Determination of Medical Acceptance: Off-label Use of Sequential IV Paclitaxel, Intraperitoneal Cisplatin, and Intraperitoneal Paclitaxel for Initial Adjuvan nt Treatment of Optimally Debulked
More informationPROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC
PROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC Giorgia Mangili RUF ginecologia oncologica medica IRCCS San Raffaele Milano mangili.giorgia@hsr.it STANDARD CHEMOTHERAPY The standard chemotherapy
More informationTargeted Molecular Therapy Gynaecological Cancer Where are we now?
Targeted Molecular Therapy Gynaecological Cancer Where are we now? 0 T O M D E G R E V E S U B - S P E C I A LT Y F E L L O W G Y N A E C O L O G I C A L O N C O L O G Y U N I V E R S I T Y O F P R E T
More informationSeptember 2017 A LOOK AT PARP INHIBITORS FOR OVARIAN CANCER. Drugs Under Review. ICER Evidence Ratings. Other Benefits. Value-Based Price Benchmarks
September 2017 Drugs Under Review ICER s report reviewed the clinical effectiveness and value of olaparib (Lynparza, AstraZeneca), rucaparib (Rubraca, Clovis Oncology), and niraparib (Zejula, Tesaro),as
More informationIntraperitoneal chemotherapy: where are we going? A. Gadducci Pisa
Intraperitoneal chemotherapy: where are we going? A. Gadducci Pisa Intraperitoneal Chemotherapy (IP) in advanced ovarian cancer (EOC): Rationale The spread of disease is often limited to the peritoneal
More informationOptimizing DNA Damage Response- Targeting Therapies: Focus on Genetic Testing and Counseling
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of May 2017. The content and views presented in this educational activity are those of the
More informationPARP Inhibitors: Patients Selection. Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016
PARP Inhibitors: Patients Selection Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016 OVARIAN CANCER (OC): MULTIPLES DISEASES Different types with different behaviour
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Cancer of the Ovary
North of Scotland Cancer Network Cancer of the Ovary Based on WOSCAN CMG with further extensive consultation within NOSCAN UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by NOSCAN Gynaecology Cancer
More informationOVARIAN CANCER Updated July 2015 by: Dr. Jenny Ko (PGY 5 Medical Oncology Resident, University of Calgary)
1 OVARIAN CANCER Updated July 2015 by: Dr. Jenny Ko (PGY 5 Medical Oncology Resident, University of Calgary) Source: UpToDate 2015, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze
More informationGOG212: Taxane Maintenance
GOG212: Taxane Maintenance Epithelial Ovarian or Primary Peritoneal Cancer Optimal or Suboptimal Cytoreduction Clinical C with normal CA125, no symptoms, normal CT Primary Carboplatin and Paclitaxel (or
More informationExpert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides
Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer Reference Slides Overview BRCA Mutations and Breast Cancer Patients with BRCA mutations have an estimated 55% to 65% cumulative
More informationGYNECOLOGIC MALIGNANCIES: Ovarian Cancer
GYNECOLOGIC MALIGNANCIES: Ovarian Cancer KRISTEN STARBUCK, MD ROSWELL PARK CANCER INSTITUTE DEPARTMENT OF SURGERY DIVISION OF GYNECOLOGIC ONCOLOGY APRIL 19 TH, 2018 Objectives Basic Cancer Statistics Discuss
More informationEpithelial Ovarian Cancer
Epithelial Ovarian Cancer GYNE/ONC Practice Guideline Dr. Alex Hammond Dr. Ian Kerr Dr. Akira Sugimoto Dr. Stephen Welch Kay Faroni Christine Gawlik Kerri Thornton Approval Date: This guideline is a statement
More informationEDUCATIONAL COMMENTARY CA 125. Learning Outcomes
EDUCATIONAL COMMENTARY CA 125 Learning Outcomes Upon completion of this exercise, participants will be able to: discuss the use of CA 125 levels in monitoring patients undergoing treatment for ovarian
More informationTREATMENT FOR RELAPSING PLATINUM SENSITIVE EPITHELIAL OVARIAN CANCER
TREATMENT FOR RELAPSING PLATINUM SENSITIVE EPITHELIAL OVARIAN CANCER Sandro Pignata, MD, PhD Sabrina Chiara Cecere, MD Uro-Gynecological Department, Division of Medical Oncology, IRCCS National Cancer
More informationNew Developments in Ovarian Cancer
New Developments in Ovarian Cancer Daniela Matei, MD Professor Gynecology Oncology Northwestern University Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Outline Recent and ongoing
More informationPractical Guidance and Strategies for PARP Inhibition. Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy
Practical Guidance and Strategies for PARP Inhibition Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy Clinical Data Maintenance therapy : BRCA-mutated or all
More informationOvarian Cancer: New insights into biology and treatment
Ovarian Cancer: New insights into biology and treatment 2018 Master Class Course Ursula A. Matulonis, MD Director, Gynecologic Oncology Brock-Wilson Family Chair Dana-Farber Cancer Institute Professor
More informationA feasibility study on maintenance of docetaxel after paclitaxel-carboplatin chemotherapy in patients with advanced ovarian cancer
Original Editorial J Gynecol Oncol Vol. 24, No. 2:154-159 http://dx.doi.org/10.3802/jgo.2013.24.2.154 pissn 2005-0380 eissn 2005-0399 A feasibility study on maintenance of docetaxel after paclitaxel-carboplatin
More informationKey Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer
Gynecologic management of women with inherited risk of gynecologic cancer C. Bethan Powell MD Kaiser Permanente Northern California Gynecologic Oncology Program Lead, Kaiser Permanente Northern California
More informationOvarian Cancer. Georgia McCann, MD. Division of Gynecologic Oncology
Ovarian Cancer Georgia McCann, MD Division of Gynecologic Oncology Myth: Ovarian cancer is a silent killer Non-specific Abdominal pain, discomfort Bloating, back pain Urinary urgency Constipation Tiredness
More informationLYNPARZA RECEIVES ADDITIONAL AND BROAD APPROVAL IN THE US FOR OVARIAN CANCER
This announcement contains inside information 18 August 2017 07:00 BST LYNPARZA RECEIVES ADDITIONAL AND BROAD APPROVAL IN THE US FOR OVARIAN CANCER Lynparza's new tablet formulation approved as maintenance
More informationGynecologic Cancers. What is Gynecologic Cancer. Who is at risk for GYN cancer? 3/1/2018 1
What is Gynecologic Cancer Gynecologic Cancers Marge Ramsdell RN, MN, OCN Madigan Army Medical Center Any cancer that starts in a woman s reproductive organs Each GYN cancer is unique 5 main types Cervical
More informationOvarian Cancer Survival. Ovarian Cancer Follow-up. Ovarian Cancer Treatment. Management of Recurrent Ovarian Carcinoma. 15,520 cancer deaths
Management of Recurrent Ovarian Carcinoma Lee-may Chen, M.D. Department of Obstetrics, Gynecology, & Reproductive Sciences UCSF Comprehensive Cancer Center Ovarian Cancer Survival United States, 28: 1
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More information10/24/14. Grand Rounds in Ovarian Cancer: Standards of Care and Novel Treatment Approaches. Disclosure. Learning Objectives
10/24/14 Grand Rounds in Ovarian Cancer: Standards of Care and Novel Treatment Approaches Jessica Gahres, PA-C Memorial Sloan Kettering Cancer Center Don S. Dizon, MD Massachusetts General Hospital Cancer
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,350 108,000 1.7 M Open access books available International authors and editors Downloads Our
More informationPoly ADP-Ribose Polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness and Value. Final Evidence Report. September 28, 2017.
Poly ADP-Ribose Polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness and Value Final Evidence Report September 28, 2017 Prepared for Institute for Clinical and Economic Review, 2017 ICER Staff/Consultants
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationESMO SUMMIT AFRICA. Latest evidence and current standard of care in advanced ovarian cancer. C.Sessa. Cape Town February 2018
ESMO SUMMIT AFRICA Latest evidence and current standard of care in advanced ovarian cancer C.Sessa IOSI, Bellinzona, CH Cape Town 14-16 February 2018 CONFLICT OF INTEREST DISCLOSURE None Ovarian carcinoma
More informationOVARIAN CANCER Updates in Screening, Early Detection and Prevention
UW MEDICINE SUSAN PATRICIA TECK MEMORIAL LECTURE October 2017 OVARIAN CANCER Updates in Screening, Early Detection and Prevention BARBARA GOFF, MD Seattle Gynecologic Society March 2018 OVARIAN CANCER
More informationCERVICAL/VULVAR CANCER CLINICAL TRIALS
CERVICAL/VULVAR CANCER CLINICAL TRIALS ALL-COMERS Primary Treatment Locally Advanced Recurrent Cervical GTFB (07-0935) TISSUE BANK ALL GYN TISSUE ETCTN (Phase II) (17-0458) LAO-MD017/#10010 Phase II Study
More informationUpdate on PARP inhibitors: opportunities and challenges in cancer therapy
Update on PARP inhibitors: opportunities and challenges in cancer therapy Vanda Salutari Unità di Ginecologia Oncologica Fondazione Policlinico Universitario A. Gemelli vanda.salutari@policlinicogemelli.it
More informationPartners: Introductions: Dr. Carolyn Johnston Deanna Cosens & Ann Garvin. Ovarian Cancer and Primary Care July 16, :00 9:00am EST 7/16/2014
Welcome To The Webinar Technical Support Ovarian Cancer and Primary Care July 16, 2014 8:00 9:00am EST In order to hear the presentation please call 1 (626) 544-0058, access code 167-314-644, followed
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationSee the latest estimates for new cases of ovarian cancer and deaths in the US and what research is currently being done.
About Ovarian Cancer Overview and Types If you have been diagnosed with ovarian cancer or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. What Is
More informationThe Role of PARP Inhibitors in Ovarian Cancer: An Emerging Picture
The Role of PARP Inhibitors in Ovarian Cancer: An Emerging Picture This satellite symposium took place on 10 th September 2017 as part of the European Society for Medical Oncology (ESMO) Congress in Madrid,
More informationPARP inhibitors for breast cancer
PARP inhibitors for breast cancer Mark Robson, MD Memorial Sloan Kettering Cancer Center Agenda Mechanism of action Clinical studies Resistance mechanisms Future directions Poly (ADP-ribose) Polymerases
More informationbreast and OVARIAN cancer
breast and OVARIAN cancer DR DAVID FENNELLY CONSULTANT MEDICAL ONCOLOGIST ST VINCENT S UNIVERSITY HOSPITAL DUBLIN HOW RELEVANT IS ONCOLOGY IN MEDICINE TODAY? Cancer is the second leading cause of death
More informationRandomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer
Randomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer Deborah K. Armstrong, M.D. Associate Professor of Oncology, Gynecology and Obstetrics Development of Intraperitoneal
More informationJemal A, Siegel R, Ward E, et al: Cancer statistics, CA: Cancer J Clin 59(4):225-49, 2009
Ovarian cancer 2010-22,500 cases diagnosed per year in the United States and 16,500 deaths per year1. - Most patients are diagnosed in late stages; no screening test exists. - Pathology: 4 different types
More informationChemotherapy in Gynecologic Malignancies
Chemotherapy in Gynecologic Malignancies Dr U.D.Bafna Professor & Head, Department of Gynecologic Oncology, Kidwai Memorial Institute of Oncology, Bangalore Chemotherapy in solid tumors is mainly adjuvant
More informationPractice of Medicine-1 Ovarian Cancer Clinical Correlation
Practice of Medicine-1 Ovarian Cancer Clinical Correlation Amir A. Jazaeri, M.D. Assistant Professor, Division of Gynecologic Oncology American Cancer Society Female Cancers 2000 Statistics Reprinted by
More informationSide Effects. PFS (months) Study Regimen No. patients. OS (months)
Study Regimen No. patients PFS (months) OS (months) Side Effects Phase II PR ov ca 1 Phase II GOG PR+PS ov ca 1 Bev (15 mg/kg) q3wks Bev (15 mg/kg) q3wks 44 4.4 10.7 HTN, Proteinuria, GI perf (11%) stopped
More informationAvastin Sample Coding
First- and Second-line Metastatic Colorectal Cancer C18.0 Malignant neoplasm of the cecum C18.1 Malignant neoplasm of appendix C18.2-C18.9 C19 C20 C21.8 Malignant neoplasm of the colon, various sites Malignant
More informationRicombinazione omologa nel carcinoma ovarico: BRCA e oltre. F. Raspagliesi MD
Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre F. Raspagliesi MD raspagliesi@istitutotumori.mi.it BRCA molecular signature in ovarian cancer In a pooled analysis of 26 observational studies
More informationState of the Science: Current status of research relevant to GCT GCT Survivors Weekend April 16, 2011
State of the Science: Current status of research relevant to GCT GCT Survivors Weekend April 16, 2011 Jubilee Brown, M.D. Associate Professor UT M.D. Anderson Cancer Center Ovarian Cancer 21,880 new cases
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lynparza) Reference Number: CP.PHAR.360 Effective Date: 10.03.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
More informationRecrui ng now. Could you help by joining this study?
Pancrea c cancer POLO study Recrui ng now AstraZeneca is looking for people with BRCA-mutated metasta c pancrea c cancer to join POLO, a clinical study to help scien sts find be er treatments for this disease
More informationDisease Update: Metastatic Breast Cancer
Disease Update: Metastatic Breast Cancer Aimee Faso, PharmD, BCOP, CPP Oncology Clinical Specialist, GI/Breast UNC Hospitals and Clinics August 2015 Objectives Identify treatment choices of metastatic
More informationCancer: recent advances and implications for underwriting
Cancer: recent advances and implications for underwriting Robert Rubens Select 74 Bristol 25 February 2010 Agenda Epidemiology - changing mortality Evidence-base for underwriting breast cancer ovarian
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationOriginal Research. Background
Original Research 849 in Carboplatin and Dose-Dense Paclitaxel Chemotherapy for Ovarian Malignancies: A Survey of NCCN Member Institutions Marina Stasenko, MD a ; R. Kevin Reynolds, MD a ; Carolyn Johnston,
More informationPoly ADP-Ribose Polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness & Value. Evidence Report. August 30, 2017.
Poly ADP-Ribose Polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness & Value Evidence Report August 30, 2017 Prepared for Institute for Clinical and Economic Review, 2017 ICER Staff/Consultants
More informationObjectives: Describe poly-adp-ribose polymerase (PARP) inhibitors mechanism of action.
1 2 3 Role of PARP Inhibitors in Metastatic Breast Cancer Catie Chatowsky, PharmD PGY1 Pharmacy Resident Disclosure: I have nothing to disclose. Objectives: Describe poly-adp-ribose polymerase (PARP) inhibitors
More informationStaging and Treatment Update for Gynecologic Malignancies
Staging and Treatment Update for Gynecologic Malignancies Bunja Rungruang, MD Medical College of Georgia No disclosures 4 th most common new cases of cancer in women 5 th and 6 th leading cancer deaths
More informationClinical guideline Published: 27 April 2011 nice.org.uk/guidance/cg122
Ovarian cancer: recognition and initial management Clinical guideline Published: 27 April 2011 nice.org.uk/guidance/cg122 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationAvastin (bevacizumab) and PARP inhibitor approvals in ovarian cancer as of June 2018
Avastin (bevacizumab) and PARP inhibitor approvals in ovarian cancer as of June 2018 The following graphic illustrates where Avastin and PARP inhibitors are currently approved in ovarian cancer. 1-4 *
More informationGYNECOLOGIC MALIGNANCIES
GYNECOLOGIC MALIGNANCIES Nuttapat Saengsukkasemsak, BP, Pharm.D, BCOP Clinical oncology pharmacist Department of Pharmacy, Siriraj hospital 29 th March 2018 Outline 1. Epithelial Ovarian Cancer 2. Cervical
More informationFrom Research to Practice: What s New in Gynecologic Cancers?
From Research to Practice: What s New in Gynecologic Cancers? David Warshal, M.D. Head, Division of Gynecologic Oncology MD Anderson Cooper Cancer Institute Associate Professor of Obstetrics and Gynecology
More informationTarceva Trial EORTC 55041
Tarceva Trial EORTC 55041 Primary Chemotherapy Tarceva consolidation 2 years Control Patients closed / 835 Leading Participating EORTC AGO-AUSTRIA, ANZGOG, GINECO, MRC/NCIC, MANGO Randomised trial on Erlotinib
More informationChapter 8 Adenocarcinoma
Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationMedicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático
Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático Dra. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau. Barcelona Introduction Ovarian cancer is the fifth
More informationIn 2017, an estimated 22,240 women will
OVARIAN CANCER Ovarian cancer remains the most deadly gynecologic malignancy in the United States. What are the practice implications of recent research results on screening, neoadjuvant chemotherapy,
More informationDisclosure. Gynecologic Cancer Genetics. Audience response. Audience response. What was the result? 47%
Disclosure Cancer Genetics I have served as a moderator for an advisory board to Genentech Lee-may Chen, M.D. Professor Department of Obstetrics, Gynecology, & Reproductive Sciences UCSF Obstetrics and
More informationNational Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007
Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationThe OReO Study. Study design & Protocol Study design Key Inclusion criteria Patient population Recruitment and retention tools
The OReO Study A Phase IIIb, Randomised, Double-blind, Placebo-controlled, multi-centre Study of Olaparib Maintenance Re-treatment in Patients with Epithelial Ovarian Cancer Previously treated with a and
More informationGranulosa Cell Tumor Monitoring and Treatment. Outline: 1. Surgery 2. Adjuvant 3. Chemo 4. Hormonal 5. Investigational. Whole Genome Sequencing
Potential Conflicts of Interest capped at a level befitting an academic role Lo B. Serving Two Masters 2010;362:669-671 Granulosa Cell Tumor Monitoring and Treatment Richard T. Penson, MD, MRCP Clinical
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Olaparib (Lynparza) for Ovarian Cancer - Resubmission September 20, 2017
pan-canadian Oncology Drug Review Final Clinical Guidance Report Olaparib (Lynparza) for Ovarian Cancer - Resubmission September 20, 2017 DISCLAIMER Not a Substitute for Professional Advice This report
More information